2018
DOI: 10.1038/s41596-018-0088-4
|View full text |Cite
|
Sign up to set email alerts
|

Publisher Correction: PhIP-Seq characterization of serum antibodies using oligonucleotide-encoded peptidomes

Abstract: The version of this paper originally published contained typesetter-introduced errors in some of the code commands, consisting of conversion of a closing backslash (\) to a forward slash (/). These errors have been corrected in the HTML and PDF versions of the protocol.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
39
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 21 publications
(39 citation statements)
references
References 0 publications
0
39
0
Order By: Relevance
“…Since we detected pan-CoV cross-reactive antibodies less frequently in plasma samples from adult donors, our results argue against a strong therapeutic benefit of intravenous immunoglobulin products to control the spread of COVID-19 disease [67]. In this context, it should be noted that large-scale antibody screening by PhIP-Seq may frequently fail to detect conformational and posttranslationally modified B cell epitopes [29]. Nontheless, we found anti-CoV antibodies in plasma of a COVID-19 patient after prolonged hospitalization and intensive care that targeted largely the same structurally conserved and functionally important regions of the viral N and S proteins (Supplementary Figure S8) as those that we detected in a sizable proportion of children, including antibodies binding to the highly conserved motif and furin-like S2' cleavage site (R¯SA[I/L]ED[I/L]LF), which provides further evidence for the clinical benefit of using convalescent plasma for the prevention and treatment of COVID-19 [68][69][70].…”
Section: Discussionmentioning
confidence: 72%
See 3 more Smart Citations
“…Since we detected pan-CoV cross-reactive antibodies less frequently in plasma samples from adult donors, our results argue against a strong therapeutic benefit of intravenous immunoglobulin products to control the spread of COVID-19 disease [67]. In this context, it should be noted that large-scale antibody screening by PhIP-Seq may frequently fail to detect conformational and posttranslationally modified B cell epitopes [29]. Nontheless, we found anti-CoV antibodies in plasma of a COVID-19 patient after prolonged hospitalization and intensive care that targeted largely the same structurally conserved and functionally important regions of the viral N and S proteins (Supplementary Figure S8) as those that we detected in a sizable proportion of children, including antibodies binding to the highly conserved motif and furin-like S2' cleavage site (R¯SA[I/L]ED[I/L]LF), which provides further evidence for the clinical benefit of using convalescent plasma for the prevention and treatment of COVID-19 [68][69][70].…”
Section: Discussionmentioning
confidence: 72%
“…To gain a deeper insight into human antibody responses to endemic HCoVs, we performed phage-immunoprecipitation sequencing (PhIP-Seq) [29][30][31] on previously collected serum or plasma samples obtained from a total of 1431 human subjects from three different cohorts.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…Recently, a potential alternative to peptide arrays has been developed: PhIP-Seq (phage immunoprecipitation sequencing') combines oligonucleotide library synthesis with high-throughput DNA sequencing analysis of phage-displayed libraries. Compared with peptide microarrays, PhIP-Seq features longer and higher-quality peptides 243 . The synthetic oligonucleotide libraries are designed to encode peptide tiles that together span a library of protein sequences (entire proteomes, for example).…”
Section: Proteomic Sequencing and Serological Profiling Of Antibody Rmentioning
confidence: 99%